Journal
GASTROENTEROLOGY
Volume 141, Issue 1, Pages 141-149Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2011.03.045
Keywords
Liver Disease; Cancer; Tumor; Prognosis; HCV
Categories
Funding
- Hoffmann-La Roche, Inc (now Genentech)
- Schering-Plough (now Merck)
- Novartis
- Romark
- National Institutes of Health [DK078772]
- Vertex Pharmaceuticals
- National Cancer Institute [5 K01 CA140861-02]
- National Institute of Diabetes & Digestive & Kidney Diseases
- National Institute of Allergy and Infectious Diseases
- National Cancer Institute
- National Center for Minority Health and Health Disparities
- General Clinical Research Center
- National Center for Research Resources, National Institutes of Health
- Celera Corporation
- National Institutes of Health
Ask authors/readers for more resources
BACKGROUND & AIMS: A single nucleotide polymorphism 61*G (rs4444903) in the epidermal growth factor (EGF) gene has been associated, in 2 case-control studies, with hepatocellular carcinoma (HCC). We tested associations between demographic, clinical, and genetic data and development of HCC, and developed a simple predictive model in a cohort of patients with chronic hepatitis C and advanced fibrosis. METHODS: Black and white subjects from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial (n = 816) were followed up prospectively for development of a definite or presumed case of HCC for a median time period of 6.1 years. We used the Cox proportional hazards regression model to determine the hazard ratio for risk of HCC and to develop prediction models. RESULTS: Subjects with EGF genotype G/G had a higher adjusted risk for HCC than those with genotype A/A (hazard ratio, 2.10; 95% confidence interval, 1.05-4.23; P = .03). After adjusting for EGF genotype, blacks had no increased risk of HCC risk compared with whites. Higher serum levels of EGF were observed among subjects with at least one G allele (P = .08); the subset of subjects with EGF G/G genotype and above-median serum levels of EGF had the highest risk of HCC. We developed a simple prediction model that included the EGF genotype to identify patients at low, intermediate, and high risk for HCC; 6-year cumulative HCC incidences were 2.3%, 10.4%, and 26%, respectively. CONCLUSIONS: We associated the EGF genotype G/G with increased risk for HCC; differences in its frequency among black and white subjects might account for differences in HCC incidence between these groups. We developed a model that incorporates EGF genotype and demographic and clinical variables to identify patients at low, intermediate, and high risk for HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available